Inogen Achieves Regulatory Milestones to Support Current and Future Products
Inogen, Inc. (Nasdaq: INGN) has achieved significant regulatory milestones, including EU MDR certification and FDA 510(k) clearance for its portable oxygen concentrators. The EU certification allows Inogen to market the Inogen One G4 and G5 in Europe, while the FDA clearance for the new Rove 4 model enhances its U.S. product lineup. The Rove 6 has already launched in Europe, with plans for the Rove 4 release in the U.S. in late 2023. These advancements affirm Inogen’s commitment to innovation in respiratory care for patients requiring oxygen therapy.
- Achieved EU MDR certification for Inogen One G4 and G5, expanding market presence in Europe.
- Received FDA 510(k) clearance for Rove 4, enhancing product offerings in the U.S.
- Launch of Rove 6 in Europe and scheduled launch of Rove 4 in the U.S. signifies growth potential.
- Regulatory approvals are subject to risks that could affect market entry and sales.
- Dependence on supply chain stability and the availability of components for manufacturing.
Inogen Announces Receipt of EU Quality Management Certification under the Medical Device Regulation for Portable Oxygen Concentrators
Inogen to Launch New Rove Series Portable Oxygen Concentrators in the US This Year
Inogen received European Medical Device Regulation (EU MDR) certification from its Notified Body, the
Additionally on
These regulatory achievements enhance Inogen’s portfolio of portable oxygen concentrator products with the addition of the Rove series. Rove 6, a new and improved 6-setting device has already been launched in European countries where reimbursement is grandfathered, and Rove 4, a 4-setting device delivering ultimate performance and portability, is expected to launch in the US by the back half of 2023 having received FDA market clearance in
“We are pleased to announce the receipt of both the EU MDR certification and
About Inogen
For more information, please visit www.inogen.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, Inogen’s expectations regarding its plans for future product releases and innovation. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks arising from regulatory approvals; risks related to the Company’s supply chain and limited availability of parts used in our POCs, the risk of further slowdowns or temporary halts to production, or cost inflation for such components; the impact of changes in reimbursement rates and reimbursement and regulatory policies; and the possible loss of key employees, customers, or suppliers. In addition, Inogen's business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Annual Report on Form 10-K for the year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005502/en/
ir@inogen.net
Source:
FAQ
What recent certifications did Inogen receive for its products?
When is the Rove 4 portable oxygen concentrator expected to launch in the U.S.?
What is the significance of the EU MDR certification for Inogen?
How does the new Rove series impact Inogen's market position?